SCHEMBL2251935

SCHEMBL2251935

COc1cccc(OC)c1-c1nc2cccc(C)n2c1Nc1ccc2c(c1)OCCO2

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 17/20 0.74
▸ GAA P10253 16/20 0.74
▸ KDM4E B2RXH2 5/20 0.68
▸ ALDH1A1 P00352 4/20 0.68
▸ MEN1 O00255 1/20 0.68
▸ KMT2A Q03164 1/20 0.68
▸ SMN1; SMN2 Q16637 4/20 0.60
▸ TP53 P04637 3/20 0.60
▸ THRB P10828 1/20 0.60
▸ TDP1 Q9NUW8 2/20 0.52
▸ LMNA P02545 2/20 0.49
▸ HPGD P15428 2/20 0.49
▸ HTT P42858 2/20 0.49
▸ L3MBTL1 Q9Y468 1/20 0.49
▸ PKM P14618 2/20 0.48
▸ TUBB4A P04350 1/20 0.48
▸ TUBB P07437 1/20 0.48
▸ TUBA3C P0DPH7 1/20 0.48
▸ TUBA1B P68363 1/20 0.48
▸ TUBA4A P68366 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2250773 0.86 GAA (0.73) MAPTGAAKDM4EALDH1A1MEN1
SCHEMBL2250222 0.85 GAA (1.00) MAPTGAAKDM4EALDH1A1MEN1
SCHEMBL2252594 0.85 MAPT (0.72) MAPTGAAKDM4EALDH1A1MEN1
SCHEMBL2256970 0.84 GAA (0.65) MAPTGAAKDM4EALDH1A1SMN1; SMN2
SCHEMBL2253480 0.83 GAA (0.69) MAPTGAAKDM4EALDH1A1MEN1
SCHEMBL2250661 0.83 GAA (0.77) MAPTGAAKDM4EALDH1A1MEN1
SCHEMBL2252235 0.82 MAPT (0.66) MAPTGAAKDM4EALDH1A1MEN1
SCHEMBL2250800 0.82 MAPT (0.71) MAPTGAAKDM4EALDH1A1MEN1
SCHEMBL2251728 0.82 MAPT (0.68) MAPTGAAKDM4EALDH1A1MEN1
SCHEMBL2250617 0.82 MAPT (0.67) MAPTGAAKDM4EALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110206607-A1 IMIDAZOL (1,2-A)PYRIDINES AND RELATED COMPOUNDS WITH ACTIVITY AT CANNABINOID CB2 RECEPTORS GE HEALTHCARE LIMITED (GB) 2011-08-25 — — US claimed
EP-2155747-A1 IMIDAZOL (1,2-A)PYRIDINES AND RELATED COMPOUNDS WITH ACTIVITY AT CANNABINOID CB2 RECEPTORS Acadia Pharmaceuticals Inc. (US) 2010-02-24 — — EP claimed
WO-2008141249-A1 IMIDAZOL (1,2-A)PYRIDINES AND RELATED COMPOUNDS WITH ACTIVITY AT CANNABINOID CB2 RECEPTORS ACADIA PHARMACEUTICALS INC. (US) 2008-11-20 — — WO claimed
EP-2155747-B1 IMIDAZOL (1,2-A)PYRIDINES AND RELATED COMPOUNDS WITH ACTIVITY AT CANNABINOID CB2 RECEPTORS GE HEALTHCARE LTD (GB) 2012-10-24 — — EP disclosed
US-20110206607-A1 IMIDAZOL (1,2-A)PYRIDINES AND RELATED COMPOUNDS WITH ACTIVITY AT CANNABINOID CB2 RECEPTORS GE HEALTHCARE LIMITED (GB) 2011-08-25 — — US disclosed
US-20110206607-A1 IMIDAZOL (1,2-A)PYRIDINES AND RELATED COMPOUNDS WITH ACTIVITY AT CANNABINOID CB2 RECEPTORS GE HEALTHCARE LIMITED (GB) 2011-08-25 — — US disclosed
US-20110206607-A1 IMIDAZOL (1,2-A)PYRIDINES AND RELATED COMPOUNDS WITH ACTIVITY AT CANNABINOID CB2 RECEPTORS GE HEALTHCARE LIMITED (GB) 2011-08-25 — — US disclosed
WO-2008141249-A1 IMIDAZOL (1,2-A)PYRIDINES AND RELATED COMPOUNDS WITH ACTIVITY AT CANNABINOID CB2 RECEPTORS ACADIA PHARMACEUTICALS INC. (US) 2008-11-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110206607-A1 IMIDAZOL (1,2-A)PYRIDINES AND RELATED COMPOUNDS WITH ACTIVITY AT CANNABINOID CB2 RECEPTORS CNR1, CNR2, GPR18 MAPT 2915/4885GAA 4087/4885KDM4E 3074/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback